Ulipristal Acetate in Adenomyosis

Area of Science:

• Gynecology
• Reproductive Medicine
• Pharmacology

Background:

• Adenomyosis involves endometrial tissue within the myometrium, causing symptoms like abnormal uterine bleeding (AUB), pelvic pain, and infertility.
• Hysterectomy is the definitive treatment, but fertility-sparing options are sought for women desiring conception.
• Ulipristal acetate, a selective progesterone receptor modulator, is approved for uterine fibroids-associated AUB.

Purpose of the Study:

• To systematically review the efficacy of ulipristal acetate in treating adenomyosis.
• To evaluate its impact on abnormal uterine bleeding, pelvic pain, and radiological findings.

Main Methods:

• A systematic literature search was conducted across PubMed, SCOPUS, and Cochrane Library.
• Eight eligible articles were identified, including one randomized clinical trial.

Main Results:

• Ulipristal acetate appears to induce partial or complete remission of AUB in adenomyosis patients.
• Evidence regarding its effects on pelvic pain and radiological findings is conflicting.
• The available data is limited, necessitating further investigation.

Conclusions:

• Ulipristal acetate shows potential for managing AUB associated with adenomyosis.
• Current evidence is insufficient to draw definitive conclusions on its efficacy for pain and imaging.
• Further high-quality research is required to establish its role in adenomyosis treatment.